News

International Men’s Day 2026: What do we know about the differences between males and females with ME/CFS.

NB: When considering information concerning groups of people with ME/CFS and those with long COVID, it is important to remember that ME/CFS is a symptom-based clinical diagnosis not a mechanistic one. It is clear there is a high degree of shared pathophysiology between ME/CFS and long COVID, and the two diagnostic labels are not mutually exclusive. Importantly, some individuals with long COVID meet ME/CFS diagnostic criteria or could have a dual diagnosis.

For International Men’s Day (IMD) 2026, ME Research UK looks at research published since November 2023 on differences between males and females with ME/CFS. This article builds on our 2023 IMD article, highlighting selected findings rather than providing a full review of the research published during this time.

A note on language: Much of the research discussed here looks at biological sex, or sex recorded at birth, rather than gender identity—how a person describes their gender. Some studies do not clearly distinguish between the two, a problem highlighted at the 2026 ISLC-PAIS conference. Using ‘sex’ and ‘gender’, or ‘male and female’ and ‘men and women’, interchangeably can make findings harder to interpret and compare. In this article, ME Research UK has used terminology in line with those used in the research papers.

What research had shown by 2023

Our 2023 article highlighted:

  • Even without illness, there are differences in how male and female bodies work. These differences can help explain why some diseases are more common in one sex and why responses to medicines and treatments can differ.
  • We still know little about differences in males and females with ME/CFS.
  • The evidence is not strong enough to draw firm conclusions, but studies suggest that males and females with ME/CFS may differ in the following ways:
    • The prevalence of ME/CFS: Reported ME/CFS rates are lower in men than in women.
    • When the illness begins: In males, ME/CFS appears to begin most often between the ages of about 10 and 19. In females, there appear to be two age ranges when it most often begins: 10–19 and 30–39.
    • Symptoms: Some studies have found less severe symptoms in men than in women. However, pressure on men to appear strong may lead some to downplay their symptoms, affecting these findings.
    • Response to exercise: Men reported slightly less fatigue overall than women. As with other symptom findings, this could reflect differences in the illness, in how symptoms are experienced, or in how they are reported.
    • Control of automatic body functions: Males had higher heart rate variability—a measure of how much the time between heartbeats changes—than females. This measure gives clues about how the body controls automatic functions, and higher values are generally seen as a sign of better health.
    • Fats in the blood: Studies have found differences in the types and amounts of blood fats in males and females with ME/CFS. These fats play a part in the body’s immune response and inflammation.
  • Much more research is needed to understand these differences and what they might mean for diagnosis and treatment.

Research update

Since November 2023, a small number of studies have been published that add to the evidence relating to sex differences in ME/CFS.

Differences identified relate to each of the following – click each heading to learn more

Other relevant research (not specifically ME/CFS)

The studies discussed above explore symptoms and biological processes in people with ME/CFS. However, due to the lack of evidence, research on immune responses and post-acute infectious syndromes (PAIS)—illnesses that continue after an infection—is also relevant to consider. Here, it is essential to note that findings from this broader research do not necessarily apply directly to ME/CFS. Again, click each of the below headings to read more.

Limitations of the research

Taken together, these studies offer useful clues, but several limitations run through the evidence:

  • Unclear use of terms: Some studies use ‘sex’ and ‘gender’ as though they mean the same thing, or do not clearly explain what they mean. This makes it harder to understand and compare the findings.
  • Too few participants: Many studies include only small numbers of people, especially males. This makes the findings less certain and means some differences may be missed.
  • Not the main question: Studies often look at differences between males and females as an extra question, rather than their main aim. The findings therefore need to be checked in studies designed specifically to explore these differences.
  • Indirect comparisons: Finding a link in one sex but not the other does not, by itself, prove a difference between them. Studies need to test those differences directly.

Limited research funding is another major barrier to understanding sex differences in ME/CFS. Our 2023 IMD article explains the history of why there is chronic underfunding for ME/CFS, but in short, illnesses more common in women than men have suffered delays in understanding, and chronic underfunding – something that is unfortunately still true for ME/CFS today.

Although funding opportunities exist, including grants from ME Research UK, overall funding for ME/CFS research – especially that for large scale projects – remains low relative to the burden of the disease, in fact a 2020 study concluded that:

“We find the disease burden of ME/CFS is double that of HIV/AIDS and over half that of breast cancer. We also find that ME/CFS is more underfunded with respect to burden than any disease in NIH’s analysis of funding and disease burden, with ME/CFS receiving roughly 7% of that commensurate with disease burden.”

These limited budgets can restrict how many people a study is able to recruit, leaving too few males or females for reliable comparisons. Including both sexes is therefore not enough: studies need to be designed to test differences between them. Sustained funding and collaboration could help researchers build the larger, more representative studies needed.

Takeaway message

Research published since November 2023 adds to evidence that ME/CFS may affect males and females differently. Studies have reported differences in symptoms, hormones, energy use, the heart and circulation, and gene activity. Alongside these findings, studies on diagnosis and symptom reporting indicate that fewer males are diagnosed with ME/CFS, and pressure to appear masculine or strong may mean that some men are undiagnosed, experience delays in diagnosis, or downplay their symptoms.

Research on long COVID and other lasting illnesses after infection offers further clues about the interplay between hormones and the immune system, but, as not all those with long COVID meet ME/CFS diagnostic criteria, findings are not automatically applicable to those with ME/CFS, and more research is needed.

It is clear that more funding is required for ME/CFS research to enable larger studies to be conducted, designed specifically to compare males and females with ME/CFS. These studies should also consider the impact of intersectionality and ensure representation from underserved groups where possible.

Dr Sarah Annesley, who is working on ME Research UK-funded projects, summarises the issue:

"ME/CFS is still poorly understood, and we know very little about whether or how it affects men and women differently. Heart disease offers a reminder of why this matters, when research began to include more women, differences in how the disease presents and responds to treatment became clearer. Not every ME/CFS study will have the funding or sample size to compare men and women properly, but we need to keep this gap in mind and work towards larger, collaborative studies that can." - Dr Sarah Annesley, 2026
Verified by MonsterInsights